THE UNIVERSITY OF BRITISH COLUMBIA
The Respiratory Evaluation Sciences Program (RESP) is a comprehensive epidemiology, health outcomes, and health economics program focused on chronic respiratory diseases (namely asthma and chronic obstructive pulmonary disease [COPD]).
We are hosted within Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, UBC. Our group has diverse expertise in using clinical data, real-world 'big' data, and computer simulations (disease modeling) techniques to evaluate the real-world effectiveness of health technologies and their 'value for money' potential. Our research has continuously been supported through multiple grants from CIHR and other agencies.
See more of our research by following categories:
Does the occurrence of a severe asthma exacerbation change the rate of subsequent events?
Does the occurrence of a severe asthma exacerbation affect the rate of subsequent events? To the best of our knowledge, this important question has not been evaluated in asthma. Conventional wisdom is that previous history of asthma exacerbations is the b...
Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
Eur Respir J. 2020 Aug 27;2002122. doi: 10.1183/13993003.02122-2020.
Predicting Severe COPD Exacerbations: Developing a Population Surveillance Approach with Administrative Data
Ann Am Thorac Soc. 2020 May 8.
RESP is hosted within Collaboration for Outcomes Research and Evaluation within UBC Faculty of Pharmaceutical Sciences. Our partners include UBC Division of Respiratory Medicine, and Centre for Clinical Epidemiology and Evaluation.
Our research has been funded by peer-reviewed grants from multiple institutions, including: